Arcutis Biotherapeutics, Inc.

WHO'M

Digital Profiler. Simply click the AI button

CUSIP

03969K108

SEDOL

BKX9VD3

CIK

0001787306

www.arcutis.com

LEI:

FIGI: BBG00QN8K4M4

ARQT

Arcutis Biotherapeutics, Inc.

GICS: - · Sector: Healthcare · Sub-Sector: Biotechnology

PROFILER

NAME

Arcutis Biotherapeutics, Inc.

ISIN

US03969K1088

TICKER

ARQT

MIC

XNAS

REUTERS

ARQT.OQ

BLOOMBERG

ARQT US

BUILD THEMEFOLIO SHARE IDEAS DISCUSS

LEVERAGE INVEST

Financial Intelligence

360°^iHub Crowd^iFeed ATH Tracker Index Tracker ETF TF Spicy² X-Billboard

FOR INVESTORS

FOR TRADERS

Securities Trading Warrants

The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by PR-Newswire.

Mon, 21.10.2024 Arcutis Biotherapeutics

US03969K1088

Once-daily, steroid-free foam designed to treat seborrheic dermatitis on all affected areas of the body, including hair-bearing regions such as the scalpClinical trial data show notable improvement in signs and symptoms, with the majority of patients experiencing reduced itching, scaling and redness, common burdens associated with seborrheic dermatitis1ZORYVE foam represents the first topical treatment for seborrheic dermatitis with a new mechanism of action approved in Canada in over 20 years2

TORONTO, Oct. 21, 2024 /CNW/ - Arcutis Canada Inc., a commercial-stage company focused on delivering meaningful innovations in immuno-dermatology, is pleased to announce that Health Canada has approved ZORYVE® (roflumilast foam 0.3%), for the treatment of seborrheic dermatitis in patients 9 years of age and older. Health Canada's approval of this steroid-free, once-daily phosphodiesterase-4 (PDE4) inhibitor brings a novel approach to the management of seborrheic dermatitis, offering a new once-daily treatment option for this chronic skin condition.

Arcutis Biotherapeutics

Technical Analysis Termsheet Terminal

Permalink

We are different

OPEN FINANCIAL

DATA & KNOWLEDGE HUB

We make the difference

Information on product placements

Legend

SMART * AD

P R O D U C T S U G G E S T I O N S

First Name *

Last Name

Email *

Subject *

i.e Feature x is not working

Issue happened on *

This page

Other page

Bug Detail *

Please give us more detailed explanation of the issue

Steps to reproduce *

Specify the steps you've done before the issue happen

Actual Result *

What's the result of the issue?

Expected Result *

What do you expect to see?

Attachment

(Optional) You can send us a screenshot, word document, or a PDF explaining the issue

Please log in to your user account. This will allow us to contact you in case of any queries.

I would like to remain anonymous.

Arcutis Biotherapeutics, Inc.

Arcutis Canada Announces Health Canada Approval of ZORYVE® Foam to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

Newsletter